Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Defining the role of MEKK2/3 in tumor progression, vascularization and metastasis

FY 2008-09

Summary
Cancer is the imbalance in the regulation of normal cellular processes, where cells grow uncontrollably leading to morbidity and mortality. Approximately, 74,000 people died of cancer in Canada in 2008 according to the Canadian Cancer Society statistics, with the majority of new cases in women being breast cancer. These disheartening statistics stress the importance of conducting research on the cellular changes that cause cancer and the development of strategies to treat the disease. Metastasis, the spread of tumor cells from a primary location in the body to another distant site, accounts for a bulk of the deaths associated with cancer, and has become the focal point of immense scientific research. However, the cellular changes and key protein components required for tumor growth and metastasis remain largely unknown. The goal of the proposed research is to identify the proteins required for tumor growth and metastasis, and to evaluate these proteins as potential drug targets for cancer therapy. Specifically, my research will focus on defining the role of mitogen activated protein kinase kinase kinases (MAP3Ks) in tumor growth and metastasis. MAP3Ks have been shown to control key genes required for cell cycle control, vascularization and cell death, representing promising anticancer targets. Following an in vivo screen for cancer-promoting proteins, the Johnson lab identified MAP3Ks MEKK2 and 3 as being critical for metastasis and/or vascularization. Based on these remarkable findings, my hypothesis is that MEKK2 and 3 function as key nodes within a cell signaling network controlling the progression of tumor growth, vascularization and metastasis and therefore, represent new anticancer targets. Experiments testing this hypothesis will be carried out under the guidance of renowned professors with some of the world's most state-of-the-art technology, with the ultimate objective of discovering new anticancer targets for therapy in Canada.
Program
CIHR Fellowship
Location
North Carolina, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
180322
Name
Duncan James S
Region
North Carolina
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Defining the role of MEKK2/3 in tumor progression, vascularization and metastasis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Anticancer Therapeutic Targets; Breast Cancer; High Throughput Quantitive Proteomics; Invasion Studies; Map3k Signaling Pathways; Mass Spectrometry; Mekk2/3; Metastasis; Protein Kinase; Rna Interference
Abstract
Cancer is the imbalance in the regulation of normal cellular processes, where cells grow uncontrollably leading to morbidity and mortality. Approximately, 74,000 people died of cancer in Canada in 2008 according to the Canadian Cancer Society statistics, with the majority of new cases in women being breast cancer. These disheartening statistics stress the importance of conducting research on the cellular changes that cause cancer and the development of strategies to treat the disease. Metastasis, the spread of tumor cells from a primary location in the body to another distant site, accounts for a bulk of the deaths associated with cancer, and has become the focal point of immense scientific research. However, the cellular changes and key protein components required for tumor growth and metastasis remain largely unknown. The goal of the proposed research is to identify the proteins required for tumor growth and metastasis, and to evaluate these proteins as potential drug targets for cancer therapy. Specifically, my research will focus on defining the role of mitogen activated protein kinase kinase kinases (MAP3Ks) in tumor growth and metastasis. MAP3Ks have been shown to control key genes required for cell cycle control, vascularization and cell death, representing promising anticancer targets. Following an in vivo screen for cancer-promoting proteins, the Johnson lab identified MAP3Ks MEKK2 and 3 as being critical for metastasis and/or vascularization. Based on these remarkable findings, my hypothesis is that MEKK2 and 3 function as key nodes within a cell signaling network controlling the progression of tumor growth, vascularization and metastasis and therefore, represent new anticancer targets. Experiments testing this hypothesis will be carried out under the guidance of renowned professors with some of the world's most state-of-the-art technology, with the ultimate objective of discovering new anticancer targets for therapy in Canada.
Competitiondate
200902
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Duncan, James S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~